Natco Pharma Limited — Results, 12-02-2025: Integrated Filing- Financial

NATCO Pharma Limited has announced a board meeting to present its financial results for the quarter and nine months ended December 31, 2024. The company reported a total income of ₹34,967 million for the nine-month period, up from ₹30,166 million in the previous year, indicating strong revenue growth. Profit before tax stood at ₹17,855 million, reflecting significant operational performance improvement.

The board has also approved an interim dividend of ₹1.50 per equity share, signaling commitment to returning value to shareholders. This positive outlook may attract investor interest, as the company's robust earnings and consistent dividends suggest a solid financial position amidst potential market uncertainties.